Hodgkin Disease
Conditions
Keywords
Hodgkin's Lymphoma, Chemotherapy, Radiation therapy, PET
Brief summary
Prognosis of patients with Hodgkin´s lymphoma (HL) has been improved significantly over the last decade. Therefore, the impact of treatment associated long-term toxicities and late effects such as second cancers increased. The purpose of this prospective multicenter trial is to show the feasibility of the treatment with ABVD alone in patients with limited stage (HL1) and intermediate stage (HL2) disease and of an intensified etoposide-free chemotherapy regimen for patients with advanced disease (HL3) including 18F-FDG-PET evaluation.
Detailed description
The aim in limited and intermediate stages is to reduce the toxicity by omitting the subsequent radiotherapy in patients with complete remission after ABVD chemotherapy. Patients with limited disease receive four cycles, patients with intermediate disease (according to the criteria of the German Hodgkin Study group, GHSG) receice six cycles of ABVD. In case of residual mass (\> 1.5 cm), additional involved field irradiation is planned. The aim in advanced disease using BACOPP-D regimen which includes cyclophosphamide, adriamycin, dacarbazine, procarbazine, prednisolone, bleomycin and vincristine, is to reduce the hematological toxicity and the secondary leukemias by omitting etoposide (in comparison to the BEACOPP escalated regimen). All patients receive eight cycles of the BACOPP-D regimen. In case of residual mass (\> 1.5 cm), additional involved field irradiation is planned. Additionally, we want to evaluate the CT- and PET-based remission status after chemotherapy and at final staging.
Interventions
DRUGCombined chemotherapy (ABVD, BACOPP-D)
PROCEDURERadiation therapy
Sponsors
Technische Universität Dresden
University Hospital Carl Gustav Carus
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
(HL1): * Histologically confirmed Hodgkin´s Lymphoma (WHO Classification 1999) 1. Classical Hodgkin Lymphoma: Nodular sclerosis (type 1 and 2) / Mixed type / Lymphocyte depleted type / Lymphocyte rich type 2. Nodular lymphocyte-predominant Hodgkin Lymphoma * Patients in stage: Clinical stage (CS) I without risk factors / CS II without risk factors * Age between 16 and 75 * Written informed consent Inclusion criteria (HL2): * Histologically confirmed Hodgkin´s Lymphoma (WHO Classification 1999) 1. Classical Hodgkin´s Lymphoma: Nodular sclerosis (type 1 and 2) / Mixed type / Lymphocyte depleted type / Lymphocyte rich type 2. Nodular lymphocyte-predominant Hodgkin Lymphoma * Patients in stage 1. Clinical stage (CS) I,II A with risk factors: Large mediastinal tumor (\>1/3 of the maximal diameter of the thoracic cavity) / Extranodal disease / Sedimentation rate ≥ 50 mm/h for patients without B-symptomes or ≥ 30 mm/h for patients with B-symptomes / ≥ 3 lymph node areas infiltrated with tumor cells 2. Clinical stage (CS) II B with risk factors: Sedimentation rate ≥ 50 mm/h for patients without B-symptomes or ≥ 30 mm/h for patients with B-symptomes / ≥ 3 lymph node areas infiltrated with tumor cells * Age between 16 and 75 * Written informed consent Inclusion criteria (HL3): * Histologically confirmed Hodgkin´s Lymphoma (WHO Classification 1999) 1. Classical Hodgkin's Lymphoma (Hodgkin's desease): Nodular sclerosis (type 1 and 2) / Mixed type / Lymphocyte depleted type / Lymphocyte rich type 2. Nodular lymphocyte-predominant Hodgkin Lymphoma * Patients in stage 1. Clinical stage (CS) II B with minimum one of the following risk factors: Large mediastinal tumor (≥1/3 of the maximal diameter of the thoracic cavity) / Extranodal disease 2. Clinical stage (CS) III 3. Clinical stage (CS) IV * Age between 16 and 65 * Written informed consent
Exclusion criteria
(HL1, HL2 and HL3): * Poor general condition not related to the lymphoma (ECOG perfomance status 3 or 4; Karnofsky Index \< 50 %) * Severe concomitant diseases: cardiac insufficiency (NYHA grade III or IV) / chronic respiratory insufficiency with hypoxemia / Hepatic insufficiency (cirrhosis, Hepatitis B or C / chronic renal insufficiency / HIV infection or other out-of-control infections / hematopoetic insufficiency (Leukocytes \< 3000/µl; Thrombocytes \< 100.000/µl / psychiatric diseases * History of previous malignancy in the last 5 years * Pregnancy * Patients not likely to comply to the requirements stemming form the participation in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Feasibility and acute toxicity of the therapy | — |
| - The Free from Therapy Failure (FFTF) rate after one year | — |
| - Event-Free Survival (EFS) rate and overall survival rate | — |
| - Evaluation of the PET as a diagnostic tool for the primary tumor staging as well for assessment of the effects of the therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| - Evaluation of the quality of life of the patients during and after the therapy | — |
| - Occurence of late toxicity after the end of the therapy | — |
Countries
Germany
Contacts
Primary ContactRalph Naumann, MD
Outcome results
None listed